Copyright Reports & Markets. All rights reserved.

Global IGY Polyclonal Antibodies Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 IGY Polyclonal Antibodies Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global IGY Polyclonal Antibodies Market Size Growth Rate by Product
      • 1.4.2 Primary Antibody
      • 1.4.3 Secondary Antibody
    • 1.5 Market by End User
      • 1.5.1 Global IGY Polyclonal Antibodies Market Size Growth Rate by End User
      • 1.5.2 Academic Research
      • 1.5.3 Commercial
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global IGY Polyclonal Antibodies Market Size
      • 2.1.1 Global IGY Polyclonal Antibodies Revenue 2014-2025
      • 2.1.2 Global IGY Polyclonal Antibodies Sales 2014-2025
    • 2.2 IGY Polyclonal Antibodies Growth Rate by Regions
      • 2.2.1 Global IGY Polyclonal Antibodies Sales by Regions
      • 2.2.2 Global IGY Polyclonal Antibodies Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 IGY Polyclonal Antibodies Sales by Manufacturers
      • 3.1.1 IGY Polyclonal Antibodies Sales by Manufacturers
      • 3.1.2 IGY Polyclonal Antibodies Sales Market Share by Manufacturers
      • 3.1.3 Global IGY Polyclonal Antibodies Market Concentration Ratio (CR5 and HHI)
    • 3.2 IGY Polyclonal Antibodies Revenue by Manufacturers
      • 3.2.1 IGY Polyclonal Antibodies Revenue by Manufacturers (2014-2019)
      • 3.2.2 IGY Polyclonal Antibodies Revenue Share by Manufacturers (2014-2019)
    • 3.3 IGY Polyclonal Antibodies Price by Manufacturers
    • 3.4 IGY Polyclonal Antibodies Manufacturing Base Distribution, Product Types
      • 3.4.1 IGY Polyclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers IGY Polyclonal Antibodies Product Type
      • 3.4.3 Date of International Manufacturers Enter into IGY Polyclonal Antibodies Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global IGY Polyclonal Antibodies Sales by Product
    • 4.2 Global IGY Polyclonal Antibodies Revenue by Product
    • 4.3 IGY Polyclonal Antibodies Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global IGY Polyclonal Antibodies Breakdown Data by End User

    6 North America

    • 6.1 North America IGY Polyclonal Antibodies by Countries
      • 6.1.1 North America IGY Polyclonal Antibodies Sales by Countries
      • 6.1.2 North America IGY Polyclonal Antibodies Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America IGY Polyclonal Antibodies by Product
    • 6.3 North America IGY Polyclonal Antibodies by End User

    7 Europe

    • 7.1 Europe IGY Polyclonal Antibodies by Countries
      • 7.1.1 Europe IGY Polyclonal Antibodies Sales by Countries
      • 7.1.2 Europe IGY Polyclonal Antibodies Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe IGY Polyclonal Antibodies by Product
    • 7.3 Europe IGY Polyclonal Antibodies by End User

    8 Asia Pacific

    • 8.1 Asia Pacific IGY Polyclonal Antibodies by Countries
      • 8.1.1 Asia Pacific IGY Polyclonal Antibodies Sales by Countries
      • 8.1.2 Asia Pacific IGY Polyclonal Antibodies Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific IGY Polyclonal Antibodies by Product
    • 8.3 Asia Pacific IGY Polyclonal Antibodies by End User

    9 Central & South America

    • 9.1 Central & South America IGY Polyclonal Antibodies by Countries
      • 9.1.1 Central & South America IGY Polyclonal Antibodies Sales by Countries
      • 9.1.2 Central & South America IGY Polyclonal Antibodies Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America IGY Polyclonal Antibodies by Product
    • 9.3 Central & South America IGY Polyclonal Antibodies by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa IGY Polyclonal Antibodies by Countries
      • 10.1.1 Middle East and Africa IGY Polyclonal Antibodies Sales by Countries
      • 10.1.2 Middle East and Africa IGY Polyclonal Antibodies Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa IGY Polyclonal Antibodies by Product
    • 10.3 Middle East and Africa IGY Polyclonal Antibodies by End User

    11 Company Profiles

    • 11.1 Merck
      • 11.1.1 Merck Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Merck IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Merck IGY Polyclonal Antibodies Products Offered
      • 11.1.5 Merck Recent Development
    • 11.2 IGY Life Sciences
      • 11.2.1 IGY Life Sciences Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 IGY Life Sciences IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 IGY Life Sciences IGY Polyclonal Antibodies Products Offered
      • 11.2.5 IGY Life Sciences Recent Development
    • 11.3 Abcam
      • 11.3.1 Abcam Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Abcam IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Abcam IGY Polyclonal Antibodies Products Offered
      • 11.3.5 Abcam Recent Development
    • 11.4 Genway Biotech
      • 11.4.1 Genway Biotech Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Genway Biotech IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Genway Biotech IGY Polyclonal Antibodies Products Offered
      • 11.4.5 Genway Biotech Recent Development
    • 11.5 Good Biotech
      • 11.5.1 Good Biotech Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Good Biotech IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Good Biotech IGY Polyclonal Antibodies Products Offered
      • 11.5.5 Good Biotech Recent Development
    • 11.6 Gallus Immunotech
      • 11.6.1 Gallus Immunotech Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Gallus Immunotech IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Gallus Immunotech IGY Polyclonal Antibodies Products Offered
      • 11.6.5 Gallus Immunotech Recent Development
    • 11.7 Creative Diagnostics
      • 11.7.1 Creative Diagnostics Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Creative Diagnostics IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Creative Diagnostics IGY Polyclonal Antibodies Products Offered
      • 11.7.5 Creative Diagnostics Recent Development
    • 11.8 Agrisera
      • 11.8.1 Agrisera Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Agrisera IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Agrisera IGY Polyclonal Antibodies Products Offered
      • 11.8.5 Agrisera Recent Development
    • 11.9 Innovagen AB
      • 11.9.1 Innovagen AB Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Innovagen AB IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Innovagen AB IGY Polyclonal Antibodies Products Offered
      • 11.9.5 Innovagen AB Recent Development
    • 11.10 Capra Science
      • 11.10.1 Capra Science Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Capra Science IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Capra Science IGY Polyclonal Antibodies Products Offered
      • 11.10.5 Capra Science Recent Development
    • 11.11 YO Proteins
    • 11.12 GeneTex

    12 Future Forecast

    • 12.1 IGY Polyclonal Antibodies Market Forecast by Regions
      • 12.1.1 Global IGY Polyclonal Antibodies Sales Forecast by Regions 2019-2025
      • 12.1.2 Global IGY Polyclonal Antibodies Revenue Forecast by Regions 2019-2025
    • 12.2 IGY Polyclonal Antibodies Market Forecast by Product
      • 12.2.1 Global IGY Polyclonal Antibodies Sales Forecast by Product 2019-2025
      • 12.2.2 Global IGY Polyclonal Antibodies Revenue Forecast by Product 2019-2025
    • 12.3 IGY Polyclonal Antibodies Market Forecast by End User
    • 12.4 North America IGY Polyclonal Antibodies Forecast
    • 12.5 Europe IGY Polyclonal Antibodies Forecast
    • 12.6 Asia Pacific IGY Polyclonal Antibodies Forecast
    • 12.7 Central & South America IGY Polyclonal Antibodies Forecast
    • 12.8 Middle East and Africa IGY Polyclonal Antibodies Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 IGY Polyclonal Antibodies Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them.
      IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation process of IgY is also different from IgG. These biological features underlie IgY's competitive advantages over IgG. Shown in the four panels are several comparisons between IgY and IgG.
      IgY is a hen egg polyclonal antibody. Hen eggs contain more than 450 separate antibodies and when consumed, are not rejected by the human immune system.
      North America is the largest consumption place, with a consumption market share nearly 37.5% in 2017; Europe is the second largest consumption place with the consumption market share of 30% in 2017.
      The global IGY Polyclonal Antibodies market is valued at 4 million US$ in 2018 and will reach 12 million US$ by the end of 2025, growing at a CAGR of 13.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the IGY Polyclonal Antibodies market based on company, product type, end user and key regions.

      This report studies the global market size of IGY Polyclonal Antibodies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of IGY Polyclonal Antibodies in these regions.
      This research report categorizes the global IGY Polyclonal Antibodies market by top players/brands, region, type and end user. This report also studies the global IGY Polyclonal Antibodies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Merck
      IGY Life Sciences
      Abcam
      Genway Biotech
      Good Biotech
      Gallus Immunotech
      Creative Diagnostics
      Agrisera
      Innovagen AB
      Capra Science
      YO Proteins
      GeneTex

      Market size by Product
      Primary Antibody
      Secondary Antibody
      Market size by End User
      Academic Research
      Commercial

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global IGY Polyclonal Antibodies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of IGY Polyclonal Antibodies market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global IGY Polyclonal Antibodies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of IGY Polyclonal Antibodies submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of IGY Polyclonal Antibodies are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of IGY Polyclonal Antibodies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now